StoneX Group’s Atara Biotherapeutics ATRA Stock Holding History

StoneX Group’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400	Closed	-$5.13K	–	655
2023 Q4	$5.13K	Buy	+400	New	+$9.33K	﹤0.01%	575

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

StoneX Group's ATRA Position: Q1 2024 in Review

StoneX Group sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 400 shares — an estimated $5.13K sold.

StoneX Group first reported a position in ATRA in Q4 2023 and held it in 1 quarter. The position peaked at $5.13K in Q4 2023. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

StoneX Group reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
StoneX Group sold 400 Atara Biotherapeutics shares in Q1 2024, an estimated $5.13K.
StoneX Group first reported a position in Atara Biotherapeutics in Q4 2023 and held it in 1 quarter.
StoneX Group's Atara Biotherapeutics position peaked at $5.13K in Q4 2023.
82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on StoneX Group's 13F filing for Q1 2024, filed 1 May 2024.